It was a pleasure to bring our Chancellor’s Circle community together for an evening exploring the hope, hype, and evolving science of GLP-1s. Below, you can revisit the full program and catch up on a few of the most intriguing ideas from the breakout conversations you may have missed.
Following the main program, our speakers continued the conversation in four smaller breakout sessions, where guests took the discussion in very different directions. Since no one could be in four rooms at once, we captured one intriguing idea from each conversation.
Zachary Knight, PhD, and Alejandro Lopez, MD
Do GLP-1 drugs dull pleasure — or just quiet the noise around it?
One of the liveliest questions in Knight and Lopez’s breakout was whether quieting “food noise” might also dull motivation or enjoyment more broadly.
Their answer: There’s little evidence that it does. People still enjoy food; they simply think about it less and feel satisfied sooner.
Alcohol may be a curious extension of that biology. Early clinical evidence suggests GLP-1 drugs can reduce heavy drinking, although Knight cautioned against the popular assumption that they simply switch off the brain’s reward system.
Alcohol is also calories, fluid, and a substance that can cause nausea — all things GLP-1s affect. Untangling those mechanisms could reveal whether these drugs are pointing toward an entirely new approach to addiction or something more specific to alcohol.
Rushika Perera, PhD
Could a weight-loss drug protect against cancer even when it doesn’t cause weight loss?
Onstage, Perera raised a provocative question: Are these drugs’ potential effects on cancer simply a consequence of eating less and losing weight?
In the breakout, she shared an experiment that suggests the story may be more complicated.
Her team can block the brain pathway through which GLP-1 drugs suppress appetite. The animals keep eating and don’t lose weight —
yet the protective effect against pancreatic cancer remains. That points toward something happening elsewhere, perhaps in the immune system, pancreas, or other tissues.
The research is still early, but it raises a genuine possibility: some of the potential effects on cancer might eventually be separated from their effects on appetite and weight.
Suneil Koliwad, MD, PhD
Why can the same GLP-1 work so differently in different people?
Koliwad sees a striking example in his own clinic:
Some patients taking a GLP-1 experience dramatic improvements in diabetes but little or no weight loss. The medicine is clearly working in the body, yet the brain circuits that normally quiet hunger appear not to respond in the same way.
That variability points toward a future beyond trial-and-error prescribing. Researchers are investigating whether genetics and other biological clues could help predict not only who will
respond to a GLP-1, but which drug — and perhaps which dose — is right for each person.
Peter Ljubenkov, MD
What if Alzheimer’s care started years before the first symptom?
The most forward-looking part of Ljubenkov’s breakout moved beyond GLP-1s altogether. Blood tests are making it increasingly possible to
identify biological signs of Alzheimer’s before memory problems appear, creating an entirely new opportunity: prevention trials in
people who are still cognitively healthy. Researchers are now testing whether treatments that target Alzheimer’s biology can intervene
early enough to delay or prevent symptoms from emerging. Results from ongoing studies could help answer one of the field’s biggest questions:
Whether the future of Alzheimer’s care will begin years before a patient ever walks into a memory clinic.
UCSF Chancellor Sam Hawgood leads one of the world’s premier health-sciences universities and one of the nation’s leading academic health systems. He is uniquely positioned to recognize where extraordinary talent and new possibilities converge, where emerging technologies could accelerate discovery, and where timely investment could help UCSF respond to an urgent need or seize an unexpected opportunity to shape the future of health care.
